Actively Recruiting
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
Led by Stanford University · Updated on 2026-04-20
16
Participants Needed
2
Research Sites
96 weeks
Total Duration
On this page
Sponsors
S
Stanford University
Lead Sponsor
E
Epidermolysis Bullosa Research Partnership
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study objective is to see if BVEC induced C7 expression in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin following Squamous cell carcinoma (SCC) excision will normalize the invasive tumor microenvironment and reduce tumor recurrence. Prevention of SCC's in the RDEB subjects will increase their life span.
CONDITIONS
Official Title
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of generalized Recessive dystrophic epidermolysis bullosa (RDEB) demonstrated by COL7A1 mutations
- Presence of biopsy proven squamous cell carcinoma (SCC)
- Ability to understand and the willingness to provide written informed consent
- US based participants are willing to use beremagene geperpavec (BVEC)
- Subject is 18 years or older
- Participant willingness to use an effective method of contraception
You will not qualify if you...
- Inability to travel to site for study visit
- Subject is pregnant
- Subject has Metastatic SCC's or is on any current systemic treatment for SCC
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Stanford University
Redwood City, California, United States, 94063
Actively Recruiting
2
Azienda Ospedliero-Universitaia
Bari, Italy
Actively Recruiting
Research Team
K
Kunju Sridhar
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here